Related Experiment Video
Updated: Sep 16, 2025
Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
Published on: January 19, 2024
International Perspectives on Vitamin K Deficiency Bleeding in Infants: A Cross-Sectional Questionnaire-Based Survey
Nongnuch Sirachainan1, Patcharee Komvilaisak2, C Heleen van Ommen3
1Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Insights
Vitamin K deficiency bleeding (VKDB) remains a global concern despite prophylaxis. Key risks include lack of vitamin K at birth and liver disease, with barriers varying by country income.
Area of Science:
- Neonatal Medicine
- Pediatric Hematology
- Public Health
Background:
- Vitamin K deficiency bleeding (VKDB) poses a risk to neonates and infants due to low vitamin K transfer and storage.
- Global vitamin K (VK) prophylaxis at birth has reduced VKDB incidence, but it remains a significant concern.
Purpose of the Study:
- To assess the current incidence, risk factors, and outcomes of VKDB.
- To identify barriers and limitations to vitamin K prophylaxis worldwide.
Main Methods:
- A global survey of physicians managing VKDB or VK prophylaxis was conducted from 2021-2023.
- Responses from 685 physicians across 38 countries were analyzed using chi-square tests and hierarchical clustering.
Main Results:
- 42.1% of physicians reported treating 1-5 VKDB cases annually.
- Lack of VK at birth and liver disease were primary risk factors.
- Hierarchical clustering revealed geographical and economic disparities in risk factors and prophylaxis barriers, including parental refusal in high-income countries and limited VK availability in low-income countries.
Conclusions:
- VKDB persists globally despite prophylaxis efforts.
- Specific guidelines for infants with liver disease and enhanced parental education are crucial.
- Addressing global disparities in VK availability is essential for effective VKDB management.
Purpose:
Vitamin K deficiency bleeding (VKDB) can occur in neonates and infants due to low placental transfer and storage of VK. Although the incidence has decreased with global VK prophylaxis at birth, VKDB remains a concern. This study aimed to assess the recent magnitude, risk factors, and outcomes of VKDB and barriers/limitations to VK prophylaxis.
Patients And Methods:
From 2021 to 2023, a survey questionnaire was distributed to physicians managing VKDB or administering VK prophylaxis through various international and national societies. Responses were analyzed using a chi-square test and unsupervised hierarchical clustering.
Results:
Among 685 respondents from 38 countries, 289 (42.1%) reported treating 1-5 VKDB cases annually. Key risk factors included the lack of VK at birth and liver disease. Hierarchical clustering of survey responses identified three groups with shared characteristics based on geographical location and country economic status: Cluster 1 consisted of high-income countries in Europe and North America; Cluster 2 included upper- to middle-income countries in Asia; and Cluster 3 comprised low- to lower-middle-income countries in Asia. In all clusters, the lack of VK prophylaxis at birth was the most common risk factor; however, liver disease was more highly reported in Cluster 2 when compared to the other clusters. The most frequent barriers to VK prophylaxis included parental refusal of intramuscular injections in high-income countries and limited availability of VK in low- to lower-middle-income countries.
Conclusions:
Despite the implementation of VK prophylaxis, VKDB remains a global issue. Guidelines for prophylaxis in infants with liver disease should be established, and comprehensive education on VKDB complications for parents and communities is essential. The limited availability of VK in certain parts of the world should be further explored and addressed to improve the management of this preventable disease in infants.
Related Concept Videos
01:30Vitamins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:24Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:29Venous Thrombosis III: Interprofessional Care
01:25Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...